Evaluation of the prognostic role of centromere 17 gain and HER2/topoisomerase II alpha gene status and protein expression in patients with breast cancer treated with anthracycline-containing adjuvant chemotherapy: Pooled analysis of two Hellenic Cooperative Oncology Group (HeCOG) phase III trials

BMC Cancer

Volumn 13, Issue , 2013, Pages

  Fountzilas, George ^a   Dafni, Urania ^b   Bobos, Mattheos ^a   Kotoula, Vassiliki ^a   Batistatou, Anna ^c   Xanthakis, Ioannis ^a   Papadimitriou, Christos ^d   Kostopoulos, Ioannis ^a   Koletsa, Triantafillia ^a   Tsolaki, Eleftheria ^a   Televantou, Despina ^a   Timotheadou, Eleni ^a   Koutras, Angelos ^e   Klouvas, George ^f   Samantas, Epaminontas ^g   Pisanidis, Nikolaos ^h   Karanikiotis, Charisios ⁱ   Sfakianaki, Ioanna ^a   Pavlidis, Nicholas ^c   Gogas, Helen ^d   Linardou, Helena ^f   Kalogeras, Konstantine T ^a,j   Pectasides, Dimitrios ^k   Dimopoulos, Meletios A ^k   more..

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b UNIVERSITY OF ATHENS   (Greece)

^c UNIVERSITY HOSPITAL OF IOANNINA   (Greece)

^d UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^e UNIVERSITY OF PATRAS   (Greece)

^f METROPOLITAN HOSPITAL   (Greece)

^g Cancer Hospital   (Greece)

^h IKA Hospital   (Greece)

ⁱ 424 General Military Hospital   (Greece)

^j Hellenic Cooperative Oncology Group   (Greece)

^k HIPPOKRATION HOSPITAL   (Greece)

more..

Author keywords

Adjuvant chemotherapy; Anthracyclines; Breast cancer; HER2; Predictive factors; Prognostic factors; Taxanes; TOP2A; TopoIIa

Indexed keywords

ANTHRACYCLINE; CYCLOPHOSPHAMIDE; DNA TOPOISOMERASE (ATP HYDROLYSING); EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; KI 67 ANTIGEN; METHOTREXATE; PACLITAXEL; PROGESTERONE RECEPTOR; TOPOISOMERASE II ALPHA; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER HORMONE THERAPY; CANCER PROGNOSIS; CANCER SIZE; CANCER SURVIVAL; CENTROMERE; CENTROMERE 17; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE DELETION; GENE DOSAGE; GENE LOCATION; GENETIC GAIN; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MENOPAUSE; MULTIPLE CYCLE TREATMENT; ONCOGENE NEU; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PHENOTYPE; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SURVIVAL RATE; TOPOISOMERASE II ALPHA GENE;

ADULT; AGED; ANTHRACYCLINES; ANTIGENS, NEOPLASM; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CENTROMERE; CHROMOSOME ABERRATIONS; CHROMOSOMES, HUMAN, PAIR 17; CLINICAL TRIALS, PHASE III AS TOPIC; DNA TOPOISOMERASES, TYPE II; DNA-BINDING PROTEINS; FEMALE; GENE DOSAGE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; ODDS RATIO; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTOR, ERBB-2; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84875356591     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-13-163     Document Type: Article

References (79)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics. CA Cancer J Clin 2009, 59(4):225-249. 10.3322/caac.20006, 19474385.
2. La Vecchia C, Bosetti C, Lucchini F, Bertuccio P, Negri E, Boyle P, Levi F. Cancer mortality in Europe, 2000-2004, and an overview of trends since 1975. Ann Oncol 2010, 21(6):1323-1360. 10.1093/annonc/mdp530, 19948741.
3. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005, 365(9472):1687-1717. Early Breast Cancer Trialists' Collaborative Group (EBCTCG).
4. Levine MN, Whelan T. Adjuvant chemotherapy for breast cancer-30 years later. N Engl J Med 2006, 355(18):1920-1922. 10.1056/NEJMe068204, 17079767.
5. Smith I, Chua S. Medical treatment of early breast cancer. III: chemotherapy. Bmj 2006, 332(7534):161-162.
6. Doyle JJ, Neugut AI, Jacobson JS, Grann VR, Hershman DL. Chemotherapy and cardiotoxicity in older breast cancer patients: a population-based study. J Clin Oncol 2005, 23(34):8597-8605. 10.1200/JCO.2005.02.5841, 16314622.
7. Hershman D, Neugut AI, Jacobson JS, Wang J, Tsai WY, McBride R, Bennett CL, Grann VR. Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy. J Natl Cancer Inst 2007, 99(3):196-205. 10.1093/jnci/djk028, 17284714.
8. Thompson F, Emerson J, Dalton W, Yang JM, McGee D, Villar H, Knox S, Massey K, Weinstein R, Bhattacharyya A. Clonal chromosome abnormalities in human breast carcinomas. I. Twenty-eight cases with primary disease. Genes Chromosomes Cancer 1993, 7(4):185-193. 10.1002/gcc.2870070402, 7692943.
9. Zody MC, Garber M, Adams DJ, Sharpe T, Harrow J, Lupski JR, Nicholson C, Searle SM, Wilming L, Young SK. DNA sequence of human chromosome 17 and analysis of rearrangement in the human lineage. Nature 2006, 440(7087):1045-1049. 10.1038/nature04689, 2610434, 16625196.
10. Botti C, Pescatore B, Mottolese M, Sciarretta F, Greco C, Di Filippo F, Gandolfo GM, Cavaliere F, Bovani R, Varanese A. Incidence of chromosomes 1 and 17 aneusomy in breast cancer and adjacent tissue: an interphase cytogenetic study. J Am Coll Surg 2000, 190(5):530-539. 10.1016/S1072-7515(00)00252-0, 10801019.
11. Reinholz MM, Bruzek AK, Visscher DW, Lingle WL, Schroeder MJ, Perez EA, Jenkins RB. Breast cancer and aneusomy 17: implications for carcinogenesis and therapeutic response. Lancet Oncol 2009, 10(3):267-277. 10.1016/S1470-2045(09)70063-4, 19261255.
12. Salido M, Tusquets I, Corominas JM, Suarez M, Espinet B, Corzo C, Bellet M, Fabregat X, Serrano S, Sole F. Polysomy of chromosome 17 in breast cancer tumors showing an overexpression of ERBB2: a study of 175 cases using fluorescence in situ hybridization and immunohistochemistry. Breast Cancer Res 2005, 7(2):26.
13. Dal Lago L, Durbecq V, Desmedt C, Salgado R, Verjat T, Lespagnard L, Ma Y, Veys I, Di Leo A, Sotiriou C. Correction for chromosome-17 is critical for the determination of true Her-2/neu gene amplification status in breast cancer. Mol Cancer Ther 2006, 5(10):2572-2579. 10.1158/1535-7163.MCT-06-0129, 17041102.
14. Hyun CL, Lee HE, Kim KS, Kim SW, Kim JH, Choe G, Park SY. The effect of chromosome 17 polysomy on HER-2/neu status in breast cancer. J Clin Pathol 2008, 61(3):317-321.
15. Vranic S, Teruya B, Repertinger S, Ulmer P, Hagenkord J, Gatalica Z. Assessment of HER2 gene status in breast carcinomas with polysomy of chromosome 17. Cancer 2011, 117(1):48-53. 10.1002/cncr.25580, 20803611.
16. Yeh IT, Martin MA, Robetorye RS, Bolla AR, McCaskill C, Shah RK, Gorre ME, Mohammed MS, Gunn SR. Clinical validation of an array CGH test for HER2 status in breast cancer reveals that polysomy 17 is a rare event. Mod Pathol 2009, 22(9):1169-1175. 10.1038/modpathol.2009.78, 19448591.
17. Viale G. Be precise! The need to consider the mechanisms for CEP17 copy number changes in breast cancer. J Pathol 2009, 219(1):1-2. 10.1002/path.2593, 19670216.
18. Marchio C, Lambros MB, Gugliotta P, Di Cantogno LV, Botta C, Pasini B, Tan DS, Mackay A, Fenwick K, Tamber N. Does chromosome 17 centromere copy number predict polysomy in breast cancer? A fluorescence in situ hybridization and microarray-based CGH analysis. J Pathol 2009, 219(1):16-24. 10.1002/path.2574, 19670217.
19. Moelans CB, de Weger RA, van Diest PJ. Absence of chromosome 17 polysomy in breast cancer: analysis by CEP17 chromogenic in situ hybridization and multiplex ligation-dependent probe amplification. Breast Cancer Res Treat 2010, 120(1):1-7. 10.1007/s10549-009-0539-2, 19760503.
20. Tse CH, Hwang HC, Goldstein LC, Kandalaft PL, Wiley JC, Kussick SJ, Gown AM. Determining true HER2 gene status in breast cancers with polysomy by using alternative chromosome 17 reference genes: implications for anti-HER2 targeted therapy. J Clin Oncol 2011, 29(31):4168-4174. 10.1200/JCO.2011.36.0107, 21947821.
21. Moelans CB, Reis-Filho JS, van Diest PJ. Implications of rarity of chromosome 17 polysomy in breast cancer. Lancet Oncol 2011, 12(12):1087-1089. 10.1016/S1470-2045(11)70234-0, 21903472.
22. Bartlett JM, Munro AF, Dunn JA, McConkey C, Jordan S, Twelves CJ, Cameron DA, Thomas J, Campbell FM, Rea DW. Predictive markers of anthracycline benefit: a prospectively planned analysis of the UK National Epirubicin Adjuvant Trial (NEAT/BR9601). Lancet Oncol 2010, 11(3):266-274. 10.1016/S1470-2045(10)70006-1, 20079691.
23. Pauletti G, Godolphin W, Press MF, Slamon DJ. Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization. Oncogene 1996, 13(1):63-72.
24. Tanner M, Jarvinen P, Isola J. Amplification of HER-2/neu and topoisomerase IIalpha in primary and metastatic breast cancer. Cancer Res 2001, 61(14):5345-5348.
25. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987, 235(4785):177-182. 10.1126/science.3798106, 3798106.
26. Jarvinen TA, Liu ET. Simultaneous amplification of HER-2 (ERBB2) and topoisomerase IIalpha (TOP2A) genes-molecular basis for combination chemotherapy in cancer. Curr Cancer Drug Targets 2006, 6(7):579-602. 10.2174/156800906778742497, 17100565.
27. Hayes DF, Thor AD, Dressler LG, Weaver D, Edgerton S, Cowan D, Broadwater G, Goldstein LJ, Martino S, Ingle JN. HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med 2007, 357(15):1496-1506. 10.1056/NEJMoa071167, 17928597.
28. Gennari A, Sormani MP, Pronzato P, Puntoni M, Colozza M, Pfeffer U, Bruzzi P. HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials. J Natl Cancer Inst 2008, 100(1):14-20. 10.1093/jnci/djm252, 18159072.
29. Di Leo A, Larsimont D, Gancberg D, Jarvinen T, Beauduin M, Vindevoghel A, Michel J, Focan CH, Ries F, Gobert PH. HER-2 and topo-isomerase IIalpha as predictive markers in a population of node-positive breast cancer patients randomly treated with adjuvant CMF or epirubicin plus cyclophosphamide. Ann Oncol 2001, 12(8):1081-1089. 10.1023/A:1011669223035, 11583189.
30. Konecny GE, Thomssen C, Luck HJ, Untch M, Wang HJ, Kuhn W, Eidtmann H, du Bois A, Olbricht S, Steinfeld D. Her-2/neu gene amplification and response to paclitaxel in patients with metastatic breast cancer. J Natl Cancer Inst 2004, 96(15):1141-1151. 10.1093/jnci/djh198, 15292386.
31. Kellner U, Sehested M, Jensen PB, Gieseler F, Rudolph P. Culprit and victim - DNA topoisomerase II. Lancet Oncol 2002, 3(4):235-243. 10.1016/S1470-2045(02)00715-5, 12067686.
32. Beser AR, Tuzlali S, Guzey D, Dolek Guler S, Hacihanefioglu S, Dalay N. HER-2, TOP2A and chromosome 17 alterations in breast cancer. Pathol Oncol Res 2007, 13(3):180-185. 10.1007/BF02893497, 17922046.
33. Champoux JJ. DNA topoisomerases: structure, function, and mechanism. Annu Rev Biochem 2001, 70:369-413. 10.1146/annurev.biochem.70.1.369, 11395412.
34. Ju BG, Lunyak VV, Perissi V, Garcia-Bassets I, Rose DW, Glass CK, Rosenfeld MG. A topoisomerase IIbeta-mediated dsDNA break required for regulated transcription. Science 2006, 312(5781):1798-1802. 10.1126/science.1127196, 16794079.
35. Jarvinen TA, Tanner M, Barlund M, Borg A, Isola J. Characterization of topoisomerase II alpha gene amplification and deletion in breast cancer. Genes Chromosomes Cancer 1999, 26(2):142-150. 10.1002/(SICI)1098-2264(199910)26:2<142::AID-GCC6>3.0.CO;2-B, 10469452.
36. Knoop AS, Knudsen H, Balslev E, Rasmussen BB, Overgaard J, Nielsen KV, Schonau A, Gunnarsdottir K, Olsen KE, Mouridsen H. Retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil: Danish Breast Cancer Cooperative Group. J Clin Oncol 2005, 23(30):7483-7490. 10.1200/JCO.2005.11.007, 16234514.
37. Schindlbeck C, Mayr D, Olivier C, Rack B, Engelstaedter V, Jueckstock J, Jenderek C, Andergassen U, Jeschke U, Friese K. Topoisomerase IIalpha expression rather than gene amplification predicts responsiveness of adjuvant anthracycline-based chemotherapy in women with primary breast cancer. Cancer Res Clin Oncol 2010, 136(7):1029-1037.
38. Simon RM, Paik S, Hayes DF. Use of archived specimens in evaluation of prognostic and predictive biomarkers. J Natl Cancer Inst 2009, 101(21):1446-1452. 10.1093/jnci/djp335, 2782246, 19815849.
39. Fountzilas G, Skarlos D, Dafni U, Gogas H, Briasoulis E, Pectasides D, Papadimitriou C, Markopoulos C, Polychronis A, Kalofonos HP. Postoperative dose-dense sequential chemotherapy with epirubicin, followed by CMF with or without paclitaxel, in patients with high-risk operable breast cancer: a randomized phase III study conducted by the Hellenic Cooperative Oncology Group. Ann Oncol 2005, 16(11):1762-1771. 10.1093/annonc/mdi366, 16148021.
40. Fountzilas G, Dafni U, Gogas H, Linardou H, Kalofonos HP, Briasoulis E, Pectasides D, Samantas E, Bafaloukos D, Stathopoulos GP. Postoperative dose-dense sequential chemotherapy with epirubicin, paclitaxel and CMF in patients with high-risk breast cancer: safety analysis of the Hellenic Cooperative Oncology Group randomized phase III trial HE 10/00. Ann Oncol 2008, 19(5):853-860. 10.1093/annonc/mdm539, 18042835.
41. Gogas H, Dafni U, Karina M, Papadimitriou C, Batistatou A, Bobos M, Kalofonos HP, Eleftheraki AG, Timotheadou E, Bafaloukos D. Postoperative dose-dense sequential versus concomitant administration of epirubicin and paclitaxel in patients with node-positive breast cancer: 5-year results of the Hellenic Cooperative Oncology Group HE 10/00 phase III Trial. Breast Cancer Res Treatment 2012, 132(2):609-619.
42. Fountzilas G, Dafni U, Bobos M, Batistatou A, Kotoula V, Trihia H, Malamou-Mitsi V, Miliaras S, Chrisafi S, Papadopoulos S. Differential response of immunohistochemically defined breast cancer subtypes to anthracycline-based adjuvant chemotherapy with or without paclitaxel. PLoS One 2012, 7(6):e37946. 10.1371/journal.pone.0037946, 3367950, 22679488.
43. Razis E, Bobos M, Kotoula V, Eleftheraki AG, Kalofonos HP, Pavlakis K, Papakostas P, Aravantinos G, Rigakos G, Efstratiou I. Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer. Breast Cancer Research Treat 2011, 128(2):447-456.
44. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. REporting recommendations for tumor MARKer prognostic studies (REMARK). Breast Cancer Res Treat 2006, 100(2):229-235. 10.1007/s10549-006-9242-8, 16932852.
45. Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, Leighton S, Torhorst J, Mihatsch MJ, Sauter G, Kallioniemi OP. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998, 4(7):844-847. 10.1038/nm0798-844, 9662379.
46. Skacel M, Skilton B, Pettay JD, Tubbs RR. Tissue microarrays: a powerful tool for high-throughput analysis of clinical specimens: a review of the method with validation data. Appl Immunohistochem Mol Morphol 2002, 10(1):1-6. 10.1097/00022744-200203000-00001, 11893029.
47. Fountzilas G, Kourea HP, Bobos M, Televantou D, Kotoula V, Papadimitriou C, Papazisis KT, Timotheadou E, Efstratiou I, Koutras A. Paclitaxel and bevacizumab as first line combined treatment in patients with metastatic breast cancer: the Hellenic Cooperative Oncology Group experience with biological marker evaluation. Anticancer Res 2011, 31(9):3007-3018.
48. Christodoulou C, Kostopoulos I, Kalofonos HP, Lianos E, Bobos M, Briasoulis E, Gogas H, Razis E, Skarlos DV, Fountzilas G. Trastuzumab combined with pegylated liposomal doxorubicin in patients with metastatic breast cancer. phase II Study of the Hellenic Cooperative Oncology Group (HeCOG) with biomarker evaluation. Oncology 2009, 76(4):275-285. 10.1159/000207504, 19262067.
49. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007, 25(1):118-145.
50. Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, Fitzgibbons PL, Francis G, Goldstein NS, Hayes M. American society of clinical oncology/college of American pathologists guideline recommendations for immunohistochemical testing of Estrogen and progesterone receptors in breast cancer. J Clin Oncol 2010, 28(16):2784-2795. 10.1200/JCO.2009.25.6529, 2881855, 20404251.
51. Cheang MC, Chia SK, Voduc D, Gao D, Leung S, Snider J, Watson M, Davies S, Bernard PS, Parker JS. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 2009, 101(10):736-750. 10.1093/jnci/djp082, 2684553, 19436038.
52. Bhargava R, Lal P, Chen B. HER-2/neu and topoisomerase IIa gene amplification and protein expression in invasive breast carcinomas: chromogenic in situ hybridization and immunohistochemical analyses. Am J Clin Pathol 2005, 123(6):889-895. 10.1309/PCFK8YTQPYWD534F, 15899781.
53. Press MF, Sauter G, Buyse M, Bernstein L, Guzman R, Santiago A, Villalobos IE, Eiermann W, Pienkowski T, Martin M. Alteration of topoisomerase II-alpha gene in human breast cancer: association with responsiveness to anthracycline-based chemotherapy. J Clin Oncol 2011, 29(7):859-867. 10.1200/JCO.2009.27.5644, 3068060, 21189395.
54. Vanden Bempt I, Van Loo P, Drijkoningen M, Neven P, Smeets A, Christiaens MR, Paridaens R, De Wolf-Peeters C. Polysomy 17 in breast cancer: clinicopathologic significance and impact on HER-2 testing. J Clin Oncol 2008, 26(30):4869-4874. 10.1200/JCO.2007.13.4296, 18794552.
55. Perez EA, Reinholz MM, Hillman DW, Tenner KS, Schroeder MJ, Davidson NE, Martino S, Sledge GW, Harris LN, Gralow JR. HER2 and chromosome 17 effect on patient outcome in the N9831 adjuvant trastuzumab trial. J Clin Oncol 2010, 28(28):4307-4315. 10.1200/JCO.2009.26.2154, 2954132, 20697084.
56. Dafni U, Bobos M, Tsolaki E, Batistatou A, Koletsa F, Televantou D, Gogas H, Linardou H, Pectasides D, Kalogeras KT, Galani E, Koutras A, Papadimitriou CA, Fountzilas G. Effect of HER2/Topoisomerase II alpha (TOP2A) Gene Status or Protein Expression and Chromosome 17 (CEP17) Polysomy on the Outcome of Breast Cancer Patients Treated with Anthracycline-Containing Dose-Dense Sequential Adjuvant Chemotherapy with or without Paclitaxel. A pooled analysis of two Hellenic Cooperative Oncology Group (HeCOG) phase III trials. Cancer Res 2011, 71(24 Suppl):Abstract nr PD05-02.
57. Sauter G, Lee J, Bartlett JM, Slamon DJ, Press MF. Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations. J Clin Oncol 2009, 27(8):1323-1333. 10.1200/JCO.2007.14.8197, 19204209.
58. Hudis CA, Barlow WE, Costantino JP, Gray RJ, Pritchard KI, Chapman JA, Sparano JA, Hunsberger S, Enos RA, Gelber RD. Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system. J Clin Oncol 2007, 25(15):2127-2132. 10.1200/JCO.2006.10.3523, 17513820.
59. Clark GM, McGuire WL. Follow-up study of HER-2/neu amplification in primary breast cancer. Cancer Res 1991, 51(3):944-948.
60. Allred DC, Clark GM, Tandon AK, Molina R, Tormey DC, Osborne CK, Gilchrist KW, Mansour EG, Abeloff M, Eudey L. HER-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma. J Clin Oncol 1992, 10(4):599-605.
61. Bonnefoi HR. Anthracyclines, HER2, and TOP2A: the verdict. Lancet Oncol 2011, 12(12):1084-1085. 10.1016/S1470-2045(11)70241-8, 21917520.
62. Di Leo A, Desmedt C, Bartlett JM, Piette F, Ejlertsen B, Pritchard KI, Larsimont D, Poole C, Isola J, Earl H. HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data. Lancet Oncol 2011, 12(12):1134-1142. 10.1016/S1470-2045(11)70231-5, 21917518.
63. Hicks DG, Tubbs RR. Assessment of the HER2 status in breast cancer by fluorescence in situ hybridization: a technical review with interpretive guidelines. Hum Pathol 2005, 36(3):250-261. 10.1016/j.humpath.2004.11.010, 15791569.
64. Nielsen KV, Ejlertsen B, Moller S, Jensen MB, Balslev E, Muller S, Knoop A, Mouridsen HT. Lack of independent prognostic and predictive value of centromere 17 copy number changes in breast cancer patients with known HER2 and TOP2A status. Mol Oncol 2012, 6(1):88-97. 10.1016/j.molonc.2011.11.006, 22153616.
65. O'Malley FP, Chia S, Tu D, Shepherd LE, Levine MN, Bramwell VH, Andrulis IL, Pritchard KI. Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy. J Natl Cancer Inst 2009, 101(9):644-650. 10.1093/jnci/djp067, 2677575, 19401546.
66. Varga Z, Tubbs RR, Wang Z, Sun Y, Noske A, Kradolfer D, Bosshard G, Jochum W, Moch H, Ohlschlegel C. Co-amplification of the HER2 gene and chromosome 17 centromere: a potential diagnostic pitfall in HER2 testing in breast cancer. Breast Cancer Res Treat 2012, 132(3):925-935. 10.1007/s10549-011-1642-8, 21698407.
67. She X, Horvath JE, Jiang Z, Liu G, Furey TS, Christ L, Clark R, Graves T, Gulden CL, Alkan C. The structure and evolution of centromeric transition regions within the human genome. Nature 2004, 430(7002):857-864. 10.1038/nature02806, 15318213.
68. Baehner FL, Achacoso N, Maddala T, Shak S, Quesenberry CP, Goldstein LC, Gown AM, Habel LA. Human epidermal growth factor receptor 2 assessment in a case-control study: comparison of fluorescence in situ hybridization and quantitative reverse transcription polymerase chain reaction performed by central laboratories. J Clin Oncol 2010, 28(28):4300-4306. 10.1200/JCO.2009.24.8211, 20697093.
69. Zaczek A, Markiewicz A, Supernat A, Bednarz-Knoll N, Brandt B, Seroczynska B, Skokowski J, Szade J, Czapiewski P, Biernat W. Prognostic Value of TOP2A Gene Amplification and Chromosome 17 Polysomy in Early Breast Cancer. Pathol Oncol Res 2012, 18(4):885-894. 10.1007/s12253-012-9518-8, 22426810.
70. Munro AF, Cameron DA, Bartlett JM. Targeting anthracyclines in early breast cancer: new candidate predictive biomarkers emerge. Oncogene 2010, 29(38):5231-5240. 10.1038/onc.2010.286, 20676126.
71. Pritchard KI, Munro A, O'Malley FP, Tu D, Li X, Levine MN, Shepherd L, Chia S, Bartlett JM. Chromosome 17 centromere (CEP17) duplication as a predictor of anthracycline response: evidence from the NCIC Clinical Trials Group (NCIC CTG) MA.5 Trial. Breast Cancer Res Treat 2012, 131(2):541-551. 10.1007/s10549-011-1840-4, 22042366.
72. Kim A, Shin HC, Bae YK, Kim MK, Kang SH, Lee SJ, Lee EH. Multiplication of Chromosome 17 Centromere Is Associated with Prognosis in Patients with Invasive Breast Cancers Exhibiting Normal HER2 and TOP2A Status. J Breast Cancer 2012, 15(1):24-33. 10.4048/jbc.2012.15.1.24, 3318171, 22493625.
73. Vanden Bempt I, Drijkoningen M, De Wolf-Peeters C. The complexity of genotypic alterations underlying HER2-positive breast cancer: an explanation for its clinical heterogeneity. Curr Opin Oncol 2007, 19(6):552-557. 10.1097/CCO.0b013e3282f0ad8e, 17906451.
74. Hayashi N, Nakamura S, Yagata H, Shimoda Y, Ota H, Hortobagyi GN, Cristofanilli M, Ueno NT. Chromosome 17 polysomy in circulating tumor cells in patients with metastatic breast cancer: a case series. Int J Clin Oncol 2011, 16(5):596-600. 10.1007/s10147-010-0173-3, 21210173.
75. Torrisi R, Rotmensz N, Bagnardi V, Viale G, Curto BD, Dell'orto P, Veronesi P, Luini A, D'Alessandro C, Cardillo A. HER2 status in early breast cancer: relevance of cell staining patterns, gene amplification and polysomy 17. Eur J Cancer 2007, 43(16):2339-2344. 10.1016/j.ejca.2007.07.033, 17855075.
76. Krishnamurti U, Hammers JL, Atem FD, Storto PD, Silverman JF. Poor prognostic significance of unamplified chromosome 17 polysomy in invasive breast carcinoma. Mod Pathol 2009, 22(8):1044-1048. 10.1038/modpathol.2009.61, 19396150.
77. Watters AD, Going JJ, Cooke TG, Bartlett JM. Chromosome 17 aneusomy is associated with poor prognostic factors in invasive breast carcinoma. Breast Cancer Res Treat 2003, 77(2):109-114. 10.1023/A:1021399923825, 12602909.
78. Bose S, Mohammed M, Shintaku P, Rao PN. Her-2/neu gene amplification in low to moderately expressing breast cancers: possible role of chromosome 17/Her-2/neu polysomy. Breast J 2001, 7(5):337-344. 10.1046/j.1524-4741.2001.21018.x, 11906444.
79. Ross JS. Human epidermal growth factor receptor 2 testing in 2010: does chromosome 17 centromere copy number make any difference?. J Clin Oncol 2010, 28(28):4293-4295. 10.1200/JCO.2010.29.6673, 20697085.